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Background: Pharmacodynamics and pharmacogenetics are being explored in phar-
macological treatment response for major depressive disorder (MDD). Interactions 
between	genotype	and	treatment	response	may	be	dose	dependent.	In	this	study,	we	
examined whether MDD patients with Met/Met, Met/Val, and Val/Val COMT geno-
types differed in their response to bupropion in terms of depression scores.
Methods: This study utilized a convenience sample of 241 adult outpatients 
(≥18	years)	who	met	DSM-5	criteria	for	MDD	and	had	visits	at	a	Midwest	psychop-
harmacology	 clinic	 between	 February	 2016	 and	 January	 2017.	 Exclusion	 criteria	
included	various	comorbid	medical,	neurological,	and	psychiatric	conditions	and	cur-
rent use of benzodiazepines or narcotics. Participants completed genetic testing and 
the 9 question patient-rated Patient Health Questionnaire (PHQ-9) at each clinic visit 
(M	=	3.8	visits,	SD = 1.5) and were prescribed bupropion or another antidepressant 
drug.	All	participants	were	adherent	 to	pharmacotherapy	 treatment	 recommenda-
tions for >2 months following genetic testing.
Results: Participants	were	mostly	Caucasian	(85.9%)	outpatients	(154	female	and	87	
male)	who	were	44.5	years	old,	on	average	(SD	=	17.9).	For	Val	carriers,	high	bupropion	
doses resulted in significantly lower PHQ-9 scores than no bupropion (t(868)	=	5.04,	
p < .001) or low dose bupropion (t(868)	=	3.29,	p = .001). Val carriers differed sig-
nificantly from Met/Met patients in response to high dose bupropion (t(868)	=	−2.03,	
p	=	.04),	but	not	to	low	dose	bupropion.
Conclusion: High-dose bupropion is beneficial for MDD patients with Met/Val or Val/
Val COMT	genotypes,	but	not	for	patients	with	Met/Met genotype. Prospective stud-
ies are necessary to replicate this pharmacodynamic relationship between bupropion 
and COMT genotypes and explore economic and clinical outcomes.
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1  | INTRODUC TION
Major depressive disorder (MDD) is a poorly understood chronic 
illness	 characterized	 by	major	 alterations	 in	mood	 that,	 even	with	
antidepressant	treatment,	can	result	 in	significant	suicidal	 ideation	
leading	to	death	(Madsen	et	al.,	2019).	The	clinical	manifestations	of	
MDD are typically experienced as profound sadness accompanied 
by	numerous	physiological	 changes,	 such	as	disturbances	 in	 sleep,	





role,	 an	epigenetic	 factor	 in	expressing	 the	phenotypic	manifesta-
tions	of	this	disease	(Nagy,	Vaillancourt,	&	Turecki,	2018).
Given	 the	 complexity	 of	 genetic	 and	 environmental	 factors,	
clinicians employ a myriad of treatment interventions with varying 
levels	of	success	at	the	individual	patient	level	(e.g.,	psychotherapy,	
electroconvulsive	 therapy,	 and	 antidepressants).	 Pharmacotherapy	
is	a	mainstay	of	modern	MDD	treatment,	but	many	patients	do	not	
respond to initial treatment or discontinue treatment because of ad-
verse	drug	effects	 (Trivedi	 et	 al.,	 2006).	Although	many	drugs	 are	
licensed	for	use	in	MDD,	data	do	not	consistently	suggest	one	class	
or specific medication to be superior in terms of efficacy (Cipriani 
et	al.,	2018).	Thus,	therapeutic	options	frequently	depend	upon	pre-
scriber	familiarity	and	comfort,	patients’	prior	experience,	cost,	and	
other factors. Despite the discovery and commercialization of new 
antidepressants,	very	little	work	has	focused	on	prospectively	char-
acterizing a personalized approach to predicting the pharmacoge-
netic and pharmacodynamic response to a particular therapy.
The revolution in genomic medicine holds the promise of har-
nessing	genetic	data	 to	 improve	outcomes,	 increase	 the	 likelihood	
of	 tolerability,	 and	decrease	 treatment	 costs.	Pharmacogenetics	 is	
one form of personalized medicine involving the use of an individ-
ual's genomic profile to help predict optimal treatment outcomes. 
Emerging data suggest that improved outcomes as well as decreased 
costs can be obtained in mental illness patients using pharmaco-
genetics,	 as	 it	 is	 already	doing	 in	disciplines	 such	as	oncology	and	
cardiology	(Bousman,	Arandjelovic,	Mancuso,	Eyre,	&	Dunlop,	2019;	
Perlis,	Mehta,	Edwards,	Tiwari,	&	Imbens,	2018).	Genetic	variation	
is an important factor that influences the efficacy and tolerability 
(therapeutic	index)	of	pharmaceutical	agents,	including	psychotropic	
drugs.	In	fact,	many	pharmaceuticals,	including	psychotropic	drugs,	
have biomarker warnings or precautions in their prescribing infor-
mation with respect to the effect of variants of genes on the drug's 
exposure.	The	US	Food	and	Drug	Administration	(FDA,	2020)	notes	
that “Pharmacogenomics can play an important role in identifying 
responders	 and	 non-responders	 to	 medications,	 avoiding	 adverse	
events,	and	optimizing	drug	dose.”	Pharmaceutical	companies	have	
also begun to state within their prescribing information packets that 
genotypes can influence dosage and tolerability.
Several	commercial	pharmacogenetic	assays	tailored	to	psychi-
atry patients are available. The genes for which these assays test 
include pharmacokinetic (PK) genes and pharmacodynamic (PD) 
genes.	 Included	 PK	 genes	 are	 most	 often	 of	 the	 CYP450	 family,	
which encode for ubiquitous proteins responsible for the metabo-
lism of most drugs. Two of these PK genes (cytochrome P450 2D6 
(CYP2D6)	and	cytochrome	P450	2C19	(CYP2C19)),	along	with	genes	
involved	 in	hypersensitivity	reactions	 (human	 leukocyte	antigen,	B	
type,	 allele	 15:02	 (HLA-B*15:02)	 and	 human	 leukocyte	 antigen,	A	
type,	allele	31:01	(HLA-A*31:01)),	are	currently	the	four	genes	that	
have	amassed	a	 level	of	empirical	support	 to	 include	them	 in	FDA	
labeling	(Miller,	2019).
Pharmacodynamic genes encode for proteins such as transport-
ers,	 receptors,	growth	factors,	and	other	 targets.	Although	poten-
tially	actionable,	they	have	less	research	support	compared	with	the	
aforementioned	PK	genes.	A	PD	gene	 incorporated	 into	one	 such	
available pharmacogenetic assay is COMT,	which	 encodes	 for	 cat-
echol-o-methyl	 transferase,	 an	 enzyme	 responsible	 for	 the	 break-
down	of	dopamine	in	the	frontal	lobes.	A	common	variant	is	a	valine	
to	methionine	 substitution	 (val158	→	met)	 resulting	 in	 decreased	
capacity of the enzyme to degrade dopamine. Individuals with the 
Val/Val genotype display elevated enzyme activity and increased 
dopamine	 degradation;	 conversely,	 patients	who	 are	Met/Met ho-
mozygous have reduced enzyme activity and dopamine degradation 
(Sawa	&	Snyder,	2002).	Because	this	gene	affects	synaptic	dopamine	
levels,	it	is	possible	that	individuals	with	the	various	genotypes	(Val/
Val,	Met/Val,	Met/Met) at this locus may vary in their response and/
or tolerability to dopaminergic drugs.
Bupropion is a widely used antidepressant with a pro-dopami-
nergic mechanism of action. Occupancy of dopamine transporter re-
ceptors	(DAT)	by	bupropion	and	its	metabolites	averaged	26%	under	





possibly suggesting synergism of dopamine and norepinephrine 
synaptic	 transmission	 and	 therefore	 not	 requiring	 the	 80%–90%	
occupancy required by serotonin receptor transporters. To avoid 
addictive	features,	a	low	level,	slow	onset,	and	long-lasting	DAT	oc-
cupancy	 is	 preferable	 for	 antidepressant	 treatment,	 targeting	 the	
phenotype	of	reduced	positive	affect	symptoms	of	MDD,	including	
sadness,	anhedonia,	low	energy,	and	poor	motivation	(Stahl,	2013).
COMT genotyping has been useful in predicting psychostim-
ulant	 responses	 for	 attention	 deficit	 disorder	 (Myer,	 Boland,	 &	
Faraone,	2018).	Available	genetic	testing	has	been	utilized	to	pharma-
codynamically evaluate the association between COMT genotypes 
and	bupropion	for	smoking	cessation,	but	not	for	the	treatment	of	
MDD	(Salloum	et	al.,	2018).	Considering	the	biphasic	synaptic	dopa-
mine levels observed for the COMT Val/Val versus Met/Met geno-
types,	we	hypothesized	that	antidepressant	response	to	bupropion	
would be influenced by the COMT	genotype,	especially	in	comparing	
low-dose versus high-dose bupropion. This retrospective single-cen-
ter study explored the outcomes of patients treated for MDD with 
pharmacogenomic testing before initiation of treatment.
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2  | MATERIAL S AND METHODS
An	IRB-approved	retrospective	chart	review	of	241	outpatients	was	
conducted to investigate the correlation of antidepressant effects 
of bupropion with COMT gene variants on individuals who met the 
DSM-5	criteria	for	MDD	at	various	levels	of	treatment.
Participants were MDD patients at a Midwestern psychophar-
macology clinic who had available genetic testing results (Genecept 
Assay®	 v.	 2.0	 [Genomind,	 Inc.])	 conducted	 between	 1	 February	
2016	and	31	January	2017.	As	this	was	a	naturalistic	study	in	an	out-
patient	treatment	setting,	patient	treatment	plans	ranged	from	ini-
tial diagnosis to medication management for those who had failed at 
least two antidepressants in different classes with an adequate dose 
and	duration.	A	retrospective	chart	review	utilizing	electronic	health	




of	 antidepressant	medications	 at	 time	of	 each	 clinic	 visit,	 and	 the	
Patient Health Questionnaire (PHQ-9) scores at each clinic visit. The 
items in the PHQ-9 correspond to the nine symptoms listed in the 
DSM	5	for	an	MDD	diagnosis.	Additionally,	participants	met	the	fol-
lowing inclusion criteria: treated with pharmacotherapy; adherent 
to treatment recommendations based on genetic testing results for 
>2	months;	and	18	years	or	older	at	 the	time	of	 testing.	Exclusion	
criteria	included	various	comorbid	medical	conditions,	current	use	of	
benzodiazepines or narcotics; comorbid neurological conditions and 
various other psychiatric comorbidities. Bupropion doses (almost ex-
clusively	 in	the	XL	formulation)	were	categorized	as	no	bupropion,	
<200	mg	 (low	dose),	or	≥200	mg	 (high	dose).	COMT gene variants 
were classified as Met/Val,	Val/Val,	or	Met/Met.
Descriptive statistics were calculated to characterize the sample 
for	 demographics,	 COMT	 genetic	 variants,	 and	 bupropion	 dosing.	
Four	cases	had	erroneous	data	for	their	PHQ-9	scores	and	were	re-
moved. Chi-square tests of independence were used to determine 
whether COMT gene variant was related to treatment with bupro-
pion or bupropion dose at time of genetic testing or for new bupro-
pion prescriptions subsequent to genetic testing.
Multilevel models (or linear mixed-effect models) were esti-
mated. This approach allows integration of the repeated observa-
tions	for	each	case,	while	also	incorporating	the	impact	of	genetic,	
demographic,	 and	bupropion	predictors	 (Snijders	&	Bosker,	2012).	
One justification for this approach was the high intraclass correla-
tion	(42%)	observed,	suggesting	that	a	high	proportion	of	variance	
was	 due	 to	 clustering	 by	 individual.	 For	 the	 first	model,	 the	 time	
sequence of observations was coded as follows: Pregenetic repre-
sented clinic visits before genetic testing was conducted; Placebo 
represented	time	period	during	which	genetic	testing	had	occurred,	
but before results were available and incorporated into the patient 
medical	treatment	(set	at	4	weeks	after	genetic	testing).	For	these	
observations,	the	simple	effect	of	informing	the	patients	that	a	ge-
netic test is being conducted can be estimated; this effect was op-
erationalized as changes to PHQ-9 scores for this time frame. In the 
statistical	analysis,	we	are	thus	able	to	detect	a	psychological	effect	
simply due to the genetic testing process before the changes to med-
ical	treatment,	in	light	of	the	genetic	test	results,	are	implemented.
Secondly,	 patient	 demographics,	COMT	 gene	 variants,	 and	 bu-
propion dose were tested for relation to PHQ-9 scores. Time was 
also included in these models such that Time 0 represented time 
period	 before	 genetic	 testing,	 Time	 1	 represented	 visit	 coinciding	
with	 genetic	 testing,	 and	Times	 2,	 3,…,	n represented subsequent 
clinic	visits.	According	to	the	primary	study	hypothesis,	COMT ge-
netic variant was expected to moderate effects of bupropion dos-
ing	on	PHQ-9	scores.	Therefore,	an	 interaction	term	was	 included	
in	 the	model.	Age	and	gender	were	also	tested	as	covariates	 in	all	
models and retained where significant. Models were specified using 
Restricted	Maximum	 Likelihood	 and	 unstructured	 covariance	 and	
included tests of differences between all combinations of bupropion 
dose and COMT gene variant.
3  | RESULTS
This study demonstrated high dose bupropion was beneficial for 
patients with Met/Val or Val/Val	variants,	but	not	for	patients	with	
Met/Met	variants.	The	total	sample	 included	241	cases	with	1,120	
observations.	On	average,	participants	had	3.8	clinic	visits	(SD	=	1.5,	
range 1–10) from genetic testing date to 6 months after genetic test-
ing.	Other	 sample	characteristics,	 including	demographic	variables	
and COMT	genotype	variant,	are	displayed	in	Table	1.
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The distribution of COMT genotypes was typical of a largely 
Caucasian	population.	At	any	time	during	their	treatment	from	base-
line	to	up	to	6	months	after	genetic	testing,	medication	distributions	
were	 noted	 as	 39.0%	 SSRI,	 41.1%	 SNRI,	 32.4%	 vortioxetine,	 and	
49.4%	bupropion.
At	 the	 time	 of	 genetic	 testing,	 24.1%	 (n = 53) were currently 
taking	bupropion.	See	Table	2	 for	percentages	of	cases	 taking	bu-
propion and high dose bupropion by COMT gene variant. Over the 
course	of	 the	observation	period,	 16.7%	 (n = 10) Met/Met,	 22.5%	
(n = 29) Met/Val,	and	26.9%	(n = 14) Val/Val cases started a new pre-
scription for bupropion.
In tests of independence between COMT gene variant and bu-
propion,	COMT gene variant was unrelated to treatment with bupro-
pion and bupropion dose at the time of genetic testing and unrelated 
to new bupropion prescriptions subsequent to genetic testing. 
Genetic testing did have a statistically significant effect on PHQ-9 
scores,	however,	not	in	the	expected	direction	for	a	placebo	effect.	
As	shown	in	Table	3,	the	predicted	value	of	PHQ-9	was	increased	by	
0.93 units during Placebo period.
As	shown	in	Table	4,	time	and	age	were	significantly	related	to	
reduction in PHQ-9 scores. Because age was included as a separate 
predictor,	the	effect	of	time	is	the	benefit	of	treatment	visits	across	
all ages. The estimates for Met/Val and Val/Val indicate that patients 
in that category had noticeably lower PHQ-9 scores compared to 
patients with Met/Met	 gene	variant.	Also,	 a	 significant	 interaction	
between bupropion dose and COMT gene variant emerged (see 
Table 5).
High dose bupropion was beneficial for patients with Met/Val 
or Val/Val	variants,	but	not	for	patients	with	Met/Met variants. This 
interaction	 is	 illustration	 in	 Figure	 1.	 Tests	 for	 differences	 in	 pre-
dicted	values	by	level	of	bupropion	dose	show	that,	for	individuals	
with Met/Met	gene	variant,	PHQ-9	scores	did	not	differ	by	dose.	In	
contrast,	for	 individuals	with	Met/Val or Val/Val	gene	variants,	sig-
nificant declines in PHQ-9 scores emerged between no bupropion 
and high dose bupropion (t(868)	=	5.04,	p < .001) and between low 
dose bupropion and high dose bupropion (t(868)	=	3.29,	p = .001). 
Finally,	although	these	two	categories	of	COMT genetic variants did 
not	differ	significantly	in	PHQ-9	scores	at	low	dose	bupropion,	Met/
Val or Val/Val gene variants did differ significantly in response to 





commercial pharmacogenetic assays have gained traction in medi-
cine,	and	data	suggest	that	these	assays	may	be	useful	in	selecting	
appropriate pharmacotherapy and reducing healthcare costs and 
utilization	(Bousman	et	al.,	2019;	Perlis	et	al.,	2018).	The	FDA’s	Table	
of	Pharmacogenomic	Biomarkers	in	Drug	Labeling	lists	at	least	260	
medications with genomic biomarkers in their label that affect drug 
exposure	and	clinical	 response,	 risk	 for	adverse	events,	and	geno-
type-specific	dosing,	including	several	dozen	drugs	commonly	used	
by	mental	 health	 clinicians	 (FDA,	 2020).	 The	 highest	 quality	 data	
generally are considered to exist for cytochrome p450 gene-drug 
associations,	but	pharmacodynamic	gene	polymorphisms	may	also	
prove useful.
Data suggest that the distribution of cognitive flexibility/rigidity 
follows	 a	U-shaped	 curve,	 in	which	 too	 little	 or	 too	much	 synaptic	
dopamine	 in	 the	 frontal	 cortex	 can	 result	 in	 impairment	 (Cools	 &	
D’esposito,	2011;	Schacht,	2016;	Stein	et	al.,	2006).	The	biphasic	na-
ture of the COMT Val/Val versus Met/Met genotypes has lent itself 
to studies of outcomes of dopaminergic drugs. Drugs related to do-
pamine	 enhancement	 (amphetamines,	methylphenidate,	 and	COMT 
inhibitors) have been associated with greater benefit in COMT Val/Val 
individuals,	whereas	drugs	acting	via	dopamine	antagonism	(atypical	
antipsychotics) have been associated with greater benefit in Met/Met 
carriers	(Farrell,	Tunbridge,	Braeutigam,	&	Harrison,	2012;	Hamidovic,	
Dlugos,	Palmer,	&	De	wit,	2010;	Huang	et	al.,	2016;	Myer	et	al.,	2018).
TA B L E  2  Sample	size,	percentage	of	cases	taking	bupropion	
and high dose bupropion at time of genetic testing by COMT gene 
variant (n = 220)










TA B L E  3  Summary	of	multilevel	model	results	for	placebo	effect	on	PHQ-9	scores	(n = 240)
Fixed effects Estimate SE t value p > |t|
Intercept 13.80 1.06 13.05 <.001
Age −0.06 0.02 −2.78 .006
Placebo (vs. Pregenetic testing) 0.93 0.46 1.99 .047
Variance components Estimate SE z value p > |z|
Intercept (subject) 21.48 3.07 7.01 <.001
Residual 18.69 1.51 12.35 <.001
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Catechol-O-methyltransferase (COMT) metabolizes catechol-
amines;	 thus,	 the	 association	 of	 COMT genotypes in treating 
MDD has been examined in terms of treatment response for 
some	 drugs.	 For	 example,	 two	 published	 studies	 on	 the	 role	 of	
the COMT	val158met	polymorphism	in	antidepressant	treatment	
response	investigating	samples	of	102	and	346	patients,	respec-
tively,	 report	 a	 tentative	 negative	 effect	 of	 the	COMT	 158Met/
Met genotype on mirtazapine and citalopram response in MDD 
(Arias	et	al.,	2006;	Szegedi	et	al.,	2005).	Meanwhile,	a	systematic	
review	 and	 meta-analysis	 of	 pharmacogenetics	 for	 MDD,	 using	
data	from	four	studies	and	STAR-D	data,	COMT was unrelated to 
antidepressant	 (SSRI	or	non-SSRI)	 response	or	 remission	 (Niitsu,	
Fabbri,	Bentini,	&	Serretti,	 2013).	 Finally,	 in	 a	 previous	 study	of	
268	 patients	 and	 an	 age-	 and	 gender-matched	 control	 sample	
of	 557	healthy	 probands,	 a	 negative	 influence	 of	 the	 higher	 ac-
tivity COMT	 158Val/Val genotype on antidepressant treatment 
response was identified during the first 6 weeks of pharmaco-





risperidone,	 lithium,	 or	 valproate	 acid.	 This	 compromised	 treat-
ment response for patients with the COMT	158Val/Val genotype 
was conferred by the likelihood of decreased dopamine availabil-
ity,	suggesting	a	potentially	beneficial	effect	of	an	antidepressive	
add-on therapy with substances increasing dopamine availabil-
ity individually tailored according to COMT	val158met	genotype	
(Baune	et	al.,	2008).
Although	the	association	between	COMT variant and bupropion 
treatment	response	for	MDD	has	not	been	studied	previously,	bu-




antidepressant,	 bupropion	 in	 “other”	 populations	 (e.g.,	 bipolar	 de-
pression	and	elderly	populations),	and	primary	evaluation	of	side	ef-
fects	(Patel	et	al.,	2016).	Some	data	supported	bupropion	targeting	
specific	 phenotypic	 symptoms,	 but	 insufficient	 information	 was	
available	 to	 reliably	 inform	 such	 prescribing.	 Thus,	 it	 remains	 un-
certain whether bupropion pharmacodynamically augments other 
drugs.
Based	on	the	previous	literature,	we	hypothesized	that	a	spe-
cific variant of COMT,	val158	→	met,	could	affect	response	to	bu-
propion	 in	patients	with	MDD.	As	genomic	psychiatry	 is	still	 in	a	
nascent	phase,	we	first	examined	whether	genetic	testing,	in	itself,	
had	a	significant	effect	on	patients’	PHQ-9	scores.	Genetic	testing	
did	 have	 a	 statistically	 significant	 effect	 on	 PHQ-9	 scores,	 how-
ever,	not	in	the	expected	direction	for	a	placebo	effect—patients’	
scores increased significantly in the time between genetic testing 
and	incorporation	of	these	results	into	patients’	medication	plans.	
Thus,	 there	 does	 not	 appear	 to	 be	 any	 psychological	 benefit,	 in	
terms	of	depression	scores,	 in	simply	administering	genetic	tests.	
However,	 information	 garnered	 from	 the	 genetic	 screening	 was	
valuable	 in	predicting	MDD	patients’	 responses	 to	 treatment.	As	
the COMT gene variant was not the focus of medication adminis-
tration,	COMT gene variant type was unrelated to treatment with 
bupropion and bupropion dose at the time of genetic testing and 





previous studies showing no associations between COMT variant 
and	remission	or	medication	response	for	MDD	patients	(Mcleod,	
Fang,	Luo,	Scott,	&	Evans,	1994).
As	 a	 naturalistic	 study,	 several	 limitations	 exist.	 This	 was	 a	
single-center retrospective study conducted on patients in the 
Midwestern	United	States.	The	population	was	primarily	Caucasian	
females,	so	results	may	not	be	extrapolated	to	larger,	more	diverse	
populations	 of	 patients.	 Additional	 limitations	 include	 the	 lack	 of	
a clinician-based assessment outcome metric tool and an antide-
pressant	 treatment	 as	usual	 comparator	without	 genotyping.	 Self-
assessments	may	 also	 be	 biased;	 however,	 we	 have	 no	 reason	 to	
believe that these biases in self-report would differ significantly 
between patients with different COMT	 genotypes.	 That	 said,	 a	
TA B L E  4  Summary	from	multilevel	model	predicting	PHQ-9	scores	(n = 241)
Fixed effects
Parameter 
estimate SE F value p > |F|
Intercept 10.29 1.03 – –
Age −0.03 0.02 3.85 .05
Time −0.70 0.09 64.90 <.001
COMT gene variant: Met/Met versus other 2.33 1.15 1.68 .20
Bupropion dose
Low	versus	High 3.39 0.67 5.89 .003
Medium versus High 2.40 0.73
COMT gene variant × Bupropion dose
Met/Met,	Low	dose −2.86 1.17 3.27 .04
Met/Met,	Medium	dose −1.22 1.33
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clinical	assessment	of	depression,	by	a	clinician	blind	to	dosage	and	
COMT	 genotype,	 would	 provide	 additional	 strength	 to	 findings.	
Additionally,	 the	 patients	 occasionally	 used	 combination	 and	 ad-
junctive	 treatment	 for	depression.	Due	 to	our	 limited	sample	 size,	
these combinatorial treatments were not controlled for in this study. 




is beneficial for MDD patients with Val carrier COMT	genotypes,	
but not for patients with a Met/Met genotype. While prospective 
studies are necessary to replicate this pharmacodynamic relation-
ship between bupropion and COMT genotypes and explore eco-
nomic	and	clinical	outcomes,	we	believe	 that	COMT Val carriers 
(75.1%	of	patients	in	this	study)	should	be	prescribed	bupropion	
at	 doses	 ≥200	 mg.	Met/Met	 carriers	 (24.9%	 of	 patients	 in	 this	
study)	 should	avoid,	or	 cautiously	use	bupropion	 for	MDD.	The	
use	of	genetic	testing,	although	not	deterministic,	may	influence	
the	probability	of	successful	bupropion	antidepressant	response,	
especially when considered as a factor combined with depres-
sive phenotyping and past individual and family of antidepressant 
treatment responses.
Prospective work on the effectiveness of pharmacotherapy 
for MDD should include an analysis of pharmacodynamics and 
pharmacogenetic genotypes. This work provides the foundational 
elements to design a large randomized clinical trial to link the util-
ity of pharmacogenomic testing guided drug selection to clinical 
outcomes.
TA B L E  5   Predicted values and standard errors for PHQ-9 scores 
from multilevel model (n = 241)
Fixed effects
Predicted 
value SE F value p > |F|
Age
26.6	(−1	SD) 11.82 0.52 3.85 .05
44.5 (mean) 11.23 0.41
62.4 (+1 SD) 10.63 0.50
Time
1st visit (genetic 
testing)
12.00 0.85 64.90 <.001
3rd visit 10.61 0.86
5th visit 9.21 0.89
COMT gene variant
Met/Met 13.19 1.02 1.68 .20
Val/Val,	Met/Val 12.22 0.87
Bupropion dose
None 13.42 0.87 5.89 .003
Low 13.24 0.95
High 11.45 0.98
COMT gene × Bupropion dose
Met/Met	×	None 13.15 1.03 3.27 .04
Met/Met	×	Low 13.80 1.23










F I G U R E  1   PHQ-9 predicted values for 
COMT gene variant by Bupropion dose 
(n = 241)
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